FindTrial
Sign In

To check the effect of intravenous atropine in patients undergoing elective caesarean section for treating nausea and vomiting associated with spinal anaesthesia

Efficacy of intravenous atropine to treat nausea and vomiting associated with spinal anaesthesia in patients undergoing elective caesarean section A single arm observational study - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/059735
Enrollment
32
Registered
2023-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O749- Complication of anesthesia duringlabor and delivery, unspecified

Interventions

Intervention1: Atropine: 0.4mg of intravenous atropine once

Sponsors

Dr Jai Prakash Sharma
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA II-III parturients undergoing elective LSCS under subarachnoid block in whom T6 or above level will be achieved and complains of nausea and/or vomiting

Exclusion criteria

Exclusion criteria: 1) Non consenting patients 2) Drug hypersensitivity to atropine or ondansetron 3) Patients who already received anti-emetic/s within previous 6 hours 4) Patient having previous history of pre-eclampsia, eclampsia or hyperemesis gravidarum 5) Patients heart rate more than 120 beats/minute at the time of atropine administration 6) Patients undergoing elective caesarean section under general anaesthesia 7) Patients with bradycardia who already received atropine 8) Cognitively impaired 9) Age <18 years

Design outcomes

Primary

MeasureTime frame
evaluate the decrease in visual analogue scale (VAS) of nausea and vomiting associated with spinal anaesthesia in parturients after administering intravenous atropine.Timepoint: Baseline HR, BP and VAS of nausea will be recorded as and when the patient complains of nausea and vomiting. After that drug will be administered and then successive readings will be taken at intervals of 5min, 10min, 20min, 30min, 60min and 120min post drug administration—

Secondary

MeasureTime frame
1)measure hemodynamic changes with intravenous atropine (heart rate, blood pressure) 2)measure the duration of action of the antiemetic effect 3)discomfort due to drug administration if any(increase or decrease of shivering, dryness of mouth, visual disturbances etc) 4)how much is the incidence of nausea and vomiting associated with spinal anaesthesia in parturient femalesTimepoint: Intraoperative periods; baseline vitals and VAS of nausea and after 5min, 10min, 20min, 30min, 60min & 120min—

Countries

India

Contacts

Public ContactDr Jai Prakash Sharma

All India Institute of Medical Sciences, Bhopal

jaiprakash.anesth@aiimsbhopal.edu.in9425609647

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026